Company Description
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms.
Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome.
The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT.
It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin.
The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020.
PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
| Country | United States |
| IPO Date | Aug 26, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Howard J. Weisman |
Contact Details
Address: 303 South Broadway, Suite 125 Tarrytown, New York 10591 United States | |
| Phone | 914-987-2876 |
| Website | paxmedica.com |
Stock Details
| Ticker Symbol | PXMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.25 |
| CIK Code | 0001811623 |
| CUSIP Number | 70424C104 |
| ISIN Number | US70424C2035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Howard J. Weisman | Chief Executive Officer and Chairman |
| Stephen Douglas Sheldon | Chief Financial Officer and Chief Operating Officer |
| Dr. David W. Hough M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 8-K | Current Report |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 15, 2024 | ARS | Filing |
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2024 | 8-K | Current Report |
| Apr 3, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 11, 2024 | 10-K | Annual Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |